Adamax vs Semax
A side-by-side research comparison of Adamax and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adamax | Semax |
|---|---|---|
| Full name | Adamax (Semax Analog Nootropic Peptide) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research peptide | Research compound |
| Mechanism | As an ACTH/melanocortin-derived peptide analog, it is proposed to elevate BDNF and other neurotrophic factors, modulate the dopaminergic and serotonergic systems, and provide neuroprotection, similar to but reportedly more potent and longer-acting than Semax. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | ~ (short peptide) | 813.9 Da |
| Half-life | Short (extended vs Semax) | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | Intranasal or subcutaneous | Moderate (intranasal) |
| Typical dose | Low microgram-to-milligram range (research) | 200-600 mcg per dose |
| Frequency | 1-2x daily | 2-3x daily |
| Route | Intranasal or subcutaneous | Intranasal drops/spray |
Adamax reported benefits
- Cognitive enhancement and focus
- Memory support
- Neuroprotection
- BDNF elevation (proposed)
- Mood support
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.